Phase 2 Study of TLK286 in Metastatic Breast Cancer

This study has been completed.

First Received: May 6, 2002 Last Updated: January 10, 2008 History of Changes

Sponsored by:	Telik
Information provided by:	Telik
ClinicalTrials.gov Identifier:	NCT00035841

Purpose

The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

Condition	Intervention	Phase
Breast Neoplasms	Drug: TLK286	Phase II

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Phase 2 Study of TLK286 in Metastatic Breast Cancer

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

Further study details as provided by Telik:

Estimated Enrollment:

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035841

Locations

United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, Indiana
Indiana University Medical Center
Indianapolis, Indiana, United States, 46202
United States, Ohio
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

Telik

More Information

No publications provided

Study ID Numbers:	TLK286.2008
Study First Received:	May 6, 2002
Last Updated:	January 10, 2008
ClinicalTrials.gov Identifier:	NCT00035841 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Skin Diseases
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Skin Diseases
Breast Neoplasms
Breast Diseases

ClinicalTrials.gov processed this record on September 11, 2009